glp-1 obesity drug news today oct 23 2025 CVS deal puts Lilly on equal footing with Novo GLP-1 Agonists Weight Loss Drugs
Description
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
A needle-free option, 100% online.
Conclusion GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF
This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides
